Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Actavis' generics business in India
Lupin's injectables business |
| gptkbp:awards |
Excellence in Healthcare Award
Innovation in Pharmaceuticals Award Best Pharmaceutical Company Award |
| gptkbp:clinical_trial |
Conducts in various therapeutic areas
|
| gptkbp:community_engagement |
Health camps
Support for local communities Awareness programs |
| gptkbp:employees |
over 10,000
|
| gptkbp:exported_to |
to over 70 countries
|
| gptkbp:founded |
gptkb:1984
|
| gptkbp:founder |
Bhavin A. Zaveri
|
| gptkbp:head_of_state |
Karan Zaveri
|
| gptkbp:headquarters |
gptkb:Ahmedabad,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intas Pharmaceuticals
|
| gptkbp:invention |
Numerous patents in pharmaceuticals
|
| gptkbp:market |
Pharmaceuticals
|
| gptkbp:market_share |
Significant in Indian market
|
| gptkbp:operates_in |
gptkb:Europe
gptkb:India gptkb:United_States |
| gptkbp:partnership |
Various global pharmaceutical companies
Indian government for healthcare projects |
| gptkbp:production_location |
GMP certified
|
| gptkbp:products |
Generic drugs
Biopharmaceuticals Over-the-counter medications |
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:WHO gptkb:EMA TGA |
| gptkbp:research_focus |
gptkb:diabetes
gptkb:Cardiology gptkb:Oncology Neurology Infectious diseases |
| gptkbp:revenue |
over $1 billion
|
| gptkbp:social_responsibility |
Environmental sustainability
Education initiatives Healthcare initiatives |
| gptkbp:subsidiary |
gptkb:Intas_Biopharmaceuticals_Ltd.
|
| gptkbp:sustainability_practices |
Energy efficiency programs
Waste management initiatives Green manufacturing processes |
| gptkbp:website |
www.intaspharma.com
|
| gptkbp:bfsParent |
gptkb:Eisai
|
| gptkbp:bfsLayer |
5
|